Celularity enters manufacturing collaboration with BlueSphere Bio for AML cell therapy

Celularity Inc

Master Services Collaboration Agreement to manufacture BlueSphere's TCR T cell therapies for AML.
Work to be performed at Celularity's 37,000 sq ft Florham Park cGMP facility; dedicated staff and small portion of footprint used.
BlueSphere's second cell therapy product for AML will be produced; BlueSphere retains oversight.
Celularity CEO highlights revenue potential of leveraging manufacturing infrastructure for third-party clients.
BlueSphere expects to dose first patient in TCX-101 program in 1H2025 and file IND for TCX-102 in Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.